Human visfatin expression: Relationship to insulin sensitivity, intramyocellular lipids, and inflammation

Vijayalakshmi Varma, Aiwei Yao-Borengasser, Neda Rasouli, Angela M. Bodles, Bounleut Phanavanh, Mi Jeong Lee, Tasha Starks, Leslie M. Kern, Horace J. Spencer, Robert E. McGehee, Susan K. Fried, Philip A. Kern

Research output: Contribution to journalArticlepeer-review

189 Scopus citations

Abstract

Context: Visfatin (VF) is a recently described adipokine preferentially secreted by visceral adipose tissue (VAT) with insulin mimetic properties. Objective: The aim of this study was to examine the association of VF with insulin sensitivity, intramyocellular lipids (IMCL), and inflammation in humans. Design and Patients: VF mRNA was examined in paired samples of VAT and abdominal sc adipose tissue (SAT) obtained from subjects undergoing surgery. Plasma VF and VF mRNA was also examined in SAT and muscle tissue, obtained by biopsy from well-characterized subjects with normal or impaired glucose tolerance, with a wide range in body mass index (BMI) and insulin sensitivity (SI). Setting: The study was conducted at a University Hospital and General Clinical Research Center. Intervention: SI was measured, and fat and muscle biopsies were performed. In impaired glucose tolerance subjects, these procedures were performed before and after treatment with pioglitazone or metformin. Main Outcome Measures: We measured the relationship between VF and obesity, SI, adipose tissue inflammation, IMCL, and response to insulin sensitizers. Results: No significant difference in VF mRNA was seen between SAT and VAT depots. VAT VF mRNA associated positively with BMI, whereas SAT VF mRNA decreased with BMI. SAT VF correlated positively with SI, and the association of SAT VF mRNA with SI was independent of BMI. IMCL and markers of inflammation (adipose CD68 and plasma TNFα) were negatively associated with SAT VF. Impaired glucose tolerance subjects treated with pioglitazone showed no change in SAT VF mRNA despite a significant increase in SI. Plasma VF and muscle VF mRNA did not correlate with BMI or SI or IMCL, and there was no change in muscle VF with either pioglitazone or metformin treatments. Conclusion: SAT VF is highly expressed in lean, more insulinsensitive subjects and is attenuated in subjects with high IMCL, low SI, and high levels of inflammatory markers. VAT VF and SAT VF are regulated oppositely with BMI.

Original languageEnglish
Pages (from-to)666-672
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume92
Issue number2
DOIs
StatePublished - Feb 2007

Bibliographical note

Funding Information:
Disclosure Statement: V.V., A.Y.-B., A.M.B., B.P., M.-J.L., T.S., L.M.K., H.J.S., R.E.M. and S.K.F. have nothing to disclose. P.A.K. has received lecture fees from Takeda Pharmaceuticals and Merck. N.R. has received investigator initiated grant support from Takeda Pharmaceuticals and Abbott.

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint

Dive into the research topics of 'Human visfatin expression: Relationship to insulin sensitivity, intramyocellular lipids, and inflammation'. Together they form a unique fingerprint.

Cite this